1-甲基-N-(8-甲基-8-氮杂二环[3.2.1]辛-3-基)-1H-吲唑-3-甲酰胺 | 119193-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-甲基-N-(8-甲基-8-氮杂二环[3.2.1]辛-3-基)-1H-吲唑-3-甲酰胺
• 英文名称: 1-Methyl-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-1H-indazole-3-carboxamide
• 英文别名: 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)indazole-3-carboxamide
• CAS: 119193-37-2
• 化学式: C₁₇H₂₂N₄O
• 分子量: 298.4
• InChiKey: DDHAJFBBJWHSBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxamide 、 碘甲烷 生成 1-甲基-N-(8-甲基-8-氮杂二环[3.2.1]辛-3-基)-1H-吲唑-3-甲酰胺
  参考文献：
  名称：

  ROBERTSON, DAVID W.;BLOOMQUIST, WILLIAM;COHEN, MARLENE L.;REID, LEROY R.;+, J. MED. CHEM., 33,(1990) N2, C. 3176-3181

  摘要：

  DOI：

文献信息

• Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
  申请人：GLAXO GROUP LIMITED

  公开号：EP0450757A2

  公开（公告）日：1991-10-09

  The invention relates to the use of a compound which acts as an antagonist of 5-HT at 5-HT₃ receptors in the treatment of autism or another disorder originating in childhood in which there is mental retardation.

  本发明涉及一种在 5-HT₃ 受体上作为 5-HT 拮抗剂的化合物在治疗自闭症或另一种源于儿童期的精神发育迟滞疾病中的应用。
• ROBERTSON, DAVID W.;BLOOMQUIST, WILLIAM;COHEN, MARLENE L.;REID, LEROY R.;+, J. MED. CHEM., 33,(1990) N2, C. 3176-3181
  作者：ROBERTSON, DAVID W.、BLOOMQUIST, WILLIAM、COHEN, MARLENE L.、REID, LEROY R.、+

  DOI：——

  日期：——
• J. MED. CHEM., 30,(1987) N 9, 1535-1537
  作者：

  DOI：——

  日期：——
• THERAPEUTIC USE OF 5-HT3 RECEPTOR ANTAGONISTS
  申请人：SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.

  公开号：EP0422154B1

  公开（公告）日：1993-12-01
• ALISKIREN MODULATION OF NEUROGENESIS
  申请人：Barlow Carrolee

  公开号：US20090197823A1

  公开（公告）日：2009-08-06

  The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of a renin inhibitor in combination with one or more neurogenic agents. The disclosure also includes compositions and methods for stimulating or activating the formation of new nerve cells based on the application of a renin inhibitor in combination with one or more neurogenic agents.